Madi Cissé

Dr. Madi Cissé

Harvard T.H Chan School of Public Health
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JSJEAN EMMANUEL SARRY
JEAN EMMANUEL SARRY
MSMarie Sabatier
Marie Sabatier
ESEstelle Saland
Estelle Saland
GCGuillaume Cognet
Guillaume Cognet
NPNathalie Poupin
Nathalie Poupin
JSJean-Emmanuel Sarry
Jean-Emmanuel Sarry
Mutations in IDH induce epigenetic and transcriptional reprogramming, differentiation bias, and susceptibility to mitochondrial inhibitors in cancer cells. Here, we first show that cell lines, PDXs, and patients with acute myeloid leukemia (AML) harboring an IDH mutation displayed an enhanced mitochondrial oxidative metabolism. Along with an increase in TCA cycle intermediates, this AML-specific metabolic behavior mechanistically occurred through the increase in electron transport chain complex I activity, mitochondrial respiration, and methylation-driven CEBPα-induced fatty acid β-oxidation of IDH1 mutant cells. While IDH1 mutant inhibitor reduced 2-HG oncometabolite and CEBPα methylation, it failed to reverse FAO and OxPHOS. These mitochondrial activities were maintained through the inhibition of Akt and enhanced activation of peroxisome proliferator-activated receptor-γ coactivator-1 PGC1α upon IDH1 mutant inhibitor. Accordingly, OxPHOS inhibitors improved anti-AML efficacy of IDH mutant inhibitors in vivo. This work provides a scientific rationale for combinatory mitochondrial-targeted therapies to treat IDH mutant AML patients, especially those unresponsive to or relapsing from IDH mutant inhibitors.

4 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ALAirelle Lahalle
Airelle Lahalle
MLMatthieu Lacroix
Matthieu Lacroix
CBCarlo De Blasio
Carlo De Blasio
MCMadi Cissé
Madi Cissé
LLLaetitia Linares
Laetitia Linares
LCLaurent Le Cam
Laurent Le Cam
The p53 pathway is functionally inactivated in most, if not all, human cancers. The p53 protein is a central effector of numerous stress-related molecular cascades. p53 controls a safeguard mechanism that prevents accumulation of abnormal cells and their transformation by regulating DNA repair, cell cycle progression, cell death, or senescence. The multiple cellular processes regulated by p53 were more recently extended to the control of metabolism and many studies support the notion that perturbations of p53-associated metabolic activities are linked to cancer development, as well as to other pathophysiological conditions including aging, type II diabetes, and liver disease. Although much less documented than p53 metabolic activities, converging lines of evidence indicate that other key components of this tumor suppressor pathway are also involved in cellular metabolism through p53-dependent as well as p53-independent mechanisms. Thus, at least from a metabolic standpoint, the p53 pathway must be considered as a non-linear pathway, but the complex metabolic network controlled by these p53 regulators and the mechanisms by which their activities are coordinated with p53 metabolic functions remain poorly understood. In this review, we highlight some of the metabolic pathways controlled by several central components of the p53 pathway and their role in tissue homeostasis, metabolic diseases, and cancer.

10 June 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MCMadi Cissé
Madi Cissé
SPSamuel Pyrdziak
Samuel Pyrdziak
NFNelly Firmin
Nelly Firmin
LGLaurie Gayte
Laurie Gayte
MHMaud Heuillet
Maud Heuillet
LLLaetitia Linares
Laetitia Linares
Well-differentiated and dedifferentiated liposarcomas (LPSs) are characterized by a systematic amplification of the MDM2 oncogene, which encodes a key negative regulator of the p53 pathway. The molecular mechanisms underlying MDM2 overexpression while sparing wild-type p53 in LPS remain poorly understood. Here, we show that the p53-independent metabolic functions of chromatin-bound MDM2 are exacerbated in LPS and mediate an addiction to serine metabolism that sustains nucleotide synthesis and tumor growth. Treatment of LPS cells with Nutlin-3A, a pharmacological inhibitor of the MDM2-p53 interaction, stabilized p53 but unexpectedly enhanced MDM2-mediated control of serine metabolism by increasing its recruitment to chromatin, likely explaining the poor clinical efficacy of this class of MDM2 inhibitors. In contrast, genetic or pharmacological inhibition of chromatin-bound MDM2 by SP141, a distinct MDM2 inhibitor triggering its degradation, or interfering with de novo serine synthesis, impaired LPS growth both in vitro and in clinically relevant patient-derived xenograft models. Our data indicate that targeting MDM2 functions in serine metabolism represents a potential therapeutic strategy for LPS.

3 April 2026
Verified
Thesis
Closed access
MCMadi Cissé
Madi Cissé
Les liposarcomes bien différenciés et dédifférenciés (LPS) se caractérisent par une amplification systématique de l'oncogène MDM2 qui code pour un régulateur négatif clé de la voie p53. Les mécanismes moléculaires aboutissants à la surexpression de MDM2, tout en concevant p53 de type sauvage dans les LPS, restent mal compris. Ici nous montrons que les fonctions métaboliques de MDM2 associées à la chromatine et indépendantes de p53, sont exacerbées dans les LPS et entraînent une dépendance vis à vis du métabolisme de la sérine, favorisant la synthèse des nucléotides et la croissance tumorale. Le traitement des cellules de LPS avec la Nutlin-3A, un inhibiteur pharmacologique de l'interaction MDM2-p53, stabilise p53 mais améliore de manière inattendue le contrôle du métabolisme de la sérine par le biais de MDM2 en augmentant son recrutement à la chromatine, ce qui explique probablement la faible efficacité clinique de cette classe d'inhibiteurs de MDM2. En revanche, l'inhibition génétique ou pharmacologique de MDM2 par le SP141, un inhibiteur de MDM2 induisant sa dégradation ou interférant avec la synthèse de sérine de novo, nui à la croissance des LPS tant in vitro que dans des modèles de xénogreffe dérivés de patient, plus pertinents sur le plan clinique. Nos données indiquent que le ciblage des fonctions de MDM2 dans le métabolisme de la sérine, représente une stratégie thérapeutique efficace pour les LPS.